Prelude Therapeutics Inc

Prelude Therapeutics operates with a market capitalization of $371.5 million and a price-to-book ratio of 5.41, indicating a premium valuation relative to its book value. The company holds $35.3 million in cash and equivalents, while its total liabilities amount to $72.7 million, resulting in a debt-to-equity ratio of 0.0, suggesting a debt-free capital structure. The current ratio of 1.99 indicates the company has sufficient current assets to cover its current liabilities. The company reported a net loss of $99.5 million for the period, with an operating loss of $104.6 million. Return on equity (ROE) is negative at -14.5%, and return on assets (ROA) is also negative at -7.04%, reflecting poor profitability. The company's EBITDA multiple is negative at -3.22, and its enterprise value to revenue ratio is 27.7, both of which are unfavorable compared to industry norms. Prelude Therapeutics does not disclose segment-specific revenue data, but its geographic exposure is not detailed in the available financials. The company's revenue for the period was $12.14 million, indicating a small revenue base with no clear geographic diversification. The company's growth trajectory is uncertain, with no clear revenue growth or decline indicated in the available data. The company's operating cash flow is negative at -$56.3 million, and its free cash flow is -$97.9 million, indicating significant cash burn. The capital expenditure of -$67,000 is minimal, suggesting limited investment in physical assets. The company's risk profile is characterized by low liquidity and low dilution risk. No immediate filing-based liquidity or dilution flags were detected. The company's dilution potential is low, and no adjustments were applied to the valuation metrics. Recent events include analyst estimates indicating a mean price target of $6.17 and a median price target of $6.00, with a mean recommendation of 1.67 (1=strong buy, 5=strong sell). There is one strong-buy recommendation, two buy recommendations, and no hold recommendations.